SBRT for painful bone metastases: equal early relief, more durable control

Design

Systematic review and meta-analysis of comparative studies including phase 3 trials

Population

Patients with painful bone metastases treated with SBRT or conventional EBRT

Primary outcome

Pain response, local control, re-irradiation, safety and survival

Effect

Complete pain response at 6 months RR 1.43; local failure RR 0.36; re-irradiation RR 0.13

This meta-analysis pooled comparative studies, including phase 3 trials, of stereotactic body radiotherapy (SBRT) against conventional external beam radiotherapy for painful bone metastases.

At three months, pain reduction, partial and stable responses and opioid use were similar. By six months, SBRT produced more complete pain responses (RR 1.43) and less pain progression (RR 0.61). Local progression or treatment failure at eight months was lower (RR 0.36), and re-irradiation by 12 months was much less common (RR 0.13). Vertebral and other fractures, spinal cord compression, toxicity and one-year survival did not differ.

This supports choosing SBRT for patients expected to live long enough to benefit — those with oligometastatic disease or good performance status — while conventional radiotherapy remains a quick and accessible option when prognosis is short. Access to SBRT is uneven, including in India, so referral pathways matter.

• Consider SBRT for painful bone metastases in patients with longer expected survival or oligometastatic disease.
• Conventional radiotherapy remains appropriate for rapid relief when prognosis is short.
• SBRT reduced re-irradiation at one year by nearly 90% in relative terms.
• Fracture and cord compression rates were similar between techniques.
• Discuss referral to a centre offering SBRT early, as access is limited.

Why it matters

It shifts the choice of technique from the lesion to the patient's prognosis.

Don't overread it

The pooled studies included non-randomised comparisons, and the abstract does not report confidence intervals for each estimate.

The statistics, in plain English

A risk ratio of 0.13 for re-irradiation means about 87% fewer patients needed repeat treatment with SBRT. An RR of 1.43 for complete pain response means about 43% more patients were pain-free at six months.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.